Article Information
History
- January 25, 2021.
Article Versions
- Version 1 (December 16, 2020 - 16:32).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Chang-Yu Chen1,2,
- Satoshi Ueha1,2,
- Yoshiro Ishiwata1,2,
- Shigeyuki Shichino1,2,
- Shoji Yokochi1,2,
- De Yang3,
- Joost J. Oppenheim3,
- Haru Ogiwara1,2,
- Shungo Deshimaru1,2,
- Yuzuka Kanno1,4,
- Tatsuro Ogawa1,
- Shiro Shibayama5 and
- Kouji Matsushima1,2,*
- 1Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan
- 2Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 3Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA
- 4Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan
- 5Research Center of Immunology, Tsukuba Institute, ONO Pharmaceutical Co., Ltd., Tsukuba, Japan
- ↵*Corresponding Author and Lead Contact: Kouji Matsushima,koujim{at}rs.tus.ac.jp; Tokyo University of Science, 2669 Yamazaki, Noda, Chiba 278-0022, Japan